Background: Multiple myeloma (MM) is a clonal B-cell malignancy of the bone marrow. Renal impairment is a common complication of MM. So far, there is no systematic overview of MM-induced kidney disease in China. Summary: The incidence of MM is 0.6/100,000 in China. Twenty-four, 19.7, and 30.8% of all patients with MM had renal insufficiency [defined by serum creatinine (Scr) ≥2 mg/dl] at diagnosis in China mainland, Hong Kong and Taiwan, respectively. Novel criteria based on the estimated glomerular filtration rate measurements are recommended for the assessment of renal function in patients with MM with stabilized Scr. It is reported that 78% of the MM patients had a creatinine clearance rate (Ccr) <90 ml/min, and 30.5% had a Ccr <30 ml/min. The IgG type was the most prevalent in MM patients; the light-chain and IgD type usually had a higher rate of kidney damage than others. New more effective drugs, blood purification technology and peripheral blood autologous stem cell transplantation have been introduced in clinical practice. Unfortunately, the studies conducted in the patients with renal insufficiency were almost all retrospective, had a small sample size and a short follow-up time. Although new treatments such as bortezomib are more widely used than before, traditional chemotherapy is still used, also because of economic constraints. The RIFLE criteria, which seem to be appropriate to define the severity of acute kidney injury (AKI), have been extensively validated worldwide but rarely in patients with MM. It was the first time to apply the RIFLE system to analyze the natural history of MM patients with AKI retrospectively in our unit. The severity of AKI defined by using the RIFLE criteria (OR = 2.04, p = 0.06) was associated with a marginal better long-term outcome. Key Messages: Novel criteria of renal insufficiency should be introduced into practice when treating MM. The treatment of MM patients with kidney disease has been greatly improved recently. It is necessary to conduct further large randomized controlled trials of the long-term outcome in China. Facts from East and West: (1) An Scr level >2 mg/dl has been reported in 16, 21, 24, and 33% of patients with MM in cohort studies of Japan, Europe, China, and Korea, respectively. A Ccr <30 ml/min was observed in 30 and 15% of patients in Chinese and Western MM cohorts, respectively. The commonest cause of severe renal impairment (RI) in patients with MM is myeloma cast nephropathy. (2) The efficacy of novel treatments (bortezomib, carfilzomib, thalidomide, and lenalidomide) has predominantly been assessed in Western patients. Bortezomib and dexamethasone are the current standard of care for MM and severe RI in the West. Severe RI is not a contraindication to autologous stem cell transplantation (ASCT). Most of the data are from the West; there are case reports from China describing good outcomes with ASCT. The removal of free light chain by high cutoff hemodialysis is under evaluation in randomized controlled trials (RCTs) in the West. Studies in this area are not yet conducted in China. In China, new treatments, such as bortezomib, are more widely used than before and favorable results are being reported; however, RCT studies are still needed in this area to confirm the efficacy and safety of this and other novel treatments.

Keywords:
Bortezomib, China, Diagnosis, Multiple myeloma, Renal impairment
1.
Ludwig H, Miguel JS, Dimopoulos MA, et al: International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28:981-992.
2.
Surveillance epidemiology and end results. Fast Stats: an interactive tool for access to SEER cancer statistics, Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats (accessed May 8, 2013).
4.
Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65:175-181.
5.
Kyle RA, Gertz MA, Witzig TE, et al: Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
6.
Bladé J, Fernández-Llama P, Bosch F, et al: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-1893.
7.
Irish AB, Winearls CG, Littlewood T: Presentation and survival of patients with severe renal failure and myeloma. QJM 1997;90:773-780.
8.
Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al; Greek Myeloma Study Group: Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007;48:337-341.
9.
Prakash J, Niwas SS, Parekh A, et al: Multiple myeloma - Presenting as acute kidney injury. J Assoc Physicians India 2009;57:23-26.
10.
Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG: Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010;25:419-426.
11.
Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M: Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 2010;89:291-297.
12.
Kim K, Lee JH, Kim JS, et al: Clinical profiles of multiple myeloma in Asia - An Asian Myeloma Network study. Am J Hematol 2014;89:751-756.
13.
Zhao Y, Li J, Huang B, et al: Clinical evaluation of chronical renal failure in 178 patients with multiple myeloma. Chin J Nephrol 2008;24:761-762.
14.
Collins AJ, Foley RN, Chavers B, et al: United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease and end stage renal disease in the United States. Am J Kidney Dis 2012;59(1 suppl 1):A7, e1-e420.
15.
Tsakiris DJ, Stel VS, Finne P, et al: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010;25:1200-1206.
16.
Chow CC, Mo KL, Chan CK, et al: Renal impairment in patients with multiple myeloma. Hong Kong Med J 2003;9:78-82.
17.
Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 1975;36:842-854.
18.
Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
19.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO clinical practice guideline for the evaluation and management of CKD. Kidney Int Suppl 2013;3:1-150.
20.
Bellomo R, Ronco C, Kellum JA, et al; Acute Dialysis Quality Initiative workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
21.
Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
22.
Kidney Disease: Improving Global Outcomes (KDIGO) AKI Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138.
23.
Shi H, Zhang W, Li X, et al: Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: a 15-year retrospective, single center, cohort study. Leuk Lymphoma 2014;55:1076-1082.
24.
Cruz DN, Ricci Z, Ronco C: Clinical review: RIFLE and AKIN - time for reappraisal. Crit Care 2009;13:211.
25.
Anderson KC, Alsina M, Bensinger W, et al; National Comprehensive Cancer Network (NCCN): Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:118-147.
26.
Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al: VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086-6093.
27.
Li J, Zhou DB, Jiao L, et al: Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma 2009;9:394-398.
28.
Xu Y, An G, Deng Sh, et al: Clinical feature and efficacy of patients with multiple myeioma and renal impairment treated with bortezomib based chemotherapy. Chin J Hematol 2013;34:303-308.
29.
Harris E, Behrens J, Samson D, et al: Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003;122:160-161.
30.
Dimopoulos MA, Alegre A, Stadtmauer EA, et al: The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010;116:3807-3814.
31.
Paiva B, Vidriales MB, Cervero J, et al: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
32.
Rawstron AC, Child JA, de Tute RM, et al: Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540-2547.
33.
Smith A, Wisloff F, Samson D, et al: Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2006;132:410-451.
34.
Badros A, Barlogie B, Siegel E, et al: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001;114:822-829.
35.
Shi H, Zhang W, Li X, et al: Autologous peripheral blood stem cell transplantation in multiple patients with renal involvement. J Intern Med Concepts Pract 2011;6:356-360.
36.
Hutchison CA, Cockwell P, Reid S, et al: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-895.
37.
Bridoux F, Fermand JP: Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial. Adv Chronic Kidney Dis 2012;19:333-341.
38.
Shum HP, Chan KC, Chow CC, et al: Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma. Hong Kong Med J 2010;16:489-492.
39.
Barosi G, Boccadoro M, Cavo M, et al: Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89:717-741.
40.
Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial. Ann Intern Med 2005;143:777-784.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.